SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

CG Oncology Shares Climb on Positive Trial Results for Bladder Cancer Drug

By Kelly CloonanShares of CG Oncology gained after the company reported positive topline results from a Phase 3 trial evaluating its bladder cancer drug.The stock climbed 20% to $89.30 Monday. Shares have more than doubled year to date.CG Oncology said the treatment, adjuvant intravesical cretostim…

CGON

Related stories